Latest advanced breast cancer Stories

2009-02-04 12:04:00

EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that company researchers will be presenting at the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine's (OCCAM) monthly lecture series.

2008-11-03 18:00:20

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial.

2008-10-21 09:00:12

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.

2008-10-08 09:00:50

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer.

2008-10-07 09:00:15

TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.

2008-10-01 09:00:49

Today, those living with advanced breast cancer now have an online resource available specifically for them. AdvancedBreastCancerCommunity.org is the first comprehensive online resource to serve as a clearinghouse of information for those impacted by advanced breast cancer.

2008-09-30 09:00:18

Cancer drug developer Antisoma has started a Phase II trial evaluating the addition of AS1402 to the endocrine therapy letrozole in post-menopausal women receiving first-line treatment for advanced breast cancer.

2008-08-11 09:00:21

TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

2008-07-14 09:01:11

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , today announced financial results for fiscal year (FY) 2008 ended April 30, 2008.

2008-04-18 12:00:19

NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology.

Word of the Day
  • a slit in a tire to drain away surface water and improve traction.
The word 'sipe' comes from Old English and is related to 'seep'.